Skip to main content
Premium Trial:

Request an Annual Quote

Pushed a Bit Later

Novavax has pushed back both its timeline for filing for authorization for its SARS-CoV-2 vaccine and its release of a report on its vaccine trial, Bloomberg reports.

Earlier this year, Novavax reported that its vaccine had nearly a 90 percent efficacy rate in preventing COVID-19 based on data from an initial UK trial. It further said that its vaccine was highly effective against the original viral stain and the B.1.1.7 variant, but had a lower efficacy rate against the B.1.351 variant.

In March, Novavax CEO Stanley Erck told CNBC that the company was aiming for May to receive Emergency Use Authorization from the US Food and Drug Administration. But as the Hill now writes, Novavax does not plan to apply for authorization in the US, UK, and Europe until the third quarter of the year. At the same time, it now plans to release its trial report at the end of the month, later than expected, the Washington Post adds.

"We know that we're delayed from where we thought we'd be at this point," Erck tells Reuters. "Now we're giving guidance that nearly all of the major challenges have been overcome and we can clearly see the light at the end of the tunnel."

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.